The team behind eFFECTOR's SPAC deal is back after going from launch to merger in just 4 months
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
The folks who successfully launched and merged a SPAC earlier this year are back again, this time seeking to take another partner to Nasdaq through the blank-check route.
Following the debut of eFFECTOR Therapeutics, the team behind the Locust Walk Acquisition SPAC will embark on a new reverse merger attempt, according to an SEC filing. The new SPAC will be called Phoenix Biotech Acquisition, and it is penciling in $155 million for its IPO.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,600+ biopharma pros reading Endpoints daily — and it's free.